miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer

Table 1 Inhibition of miR-630 reduces sensitivity to HER-targeted drugs, lapatinib, neratinib and afatinib

Drug	Drug Conc.	Cell line	% Cell -proliferation drug + NC Inhibitor	% Cell proliferation drug + miR-630 Inhibitor	% Resistance induced by miR-630 inhibitor	p-value
Lapatinib	0.05 μM	SKBR3-Ag	50.0 ± 9.6	63.6 ± 9.1	*13.6 ± 0.8*	0.002
Lapatinib	0.7 μM	HCC1954-Ag	40.8 ± 3.6	63.7 ± 4.8	*22.9 ± 6.7*	0.039
Neratinib	0.005 μM	SKBR3-Ag	34.7 ± 6.4	43.2 ± 7.4	*8.6 ± 1.6*	0.017
Neratinib	0.005 μM	HCC1954-Ag	43.2 ± 2.3	58.2 ± 2.4	*15.1 ± 3.0*	0.019
Afatinib	0.005 μM	SKBR3-Ag	47.7 ± 5.2	62.3 ± 4.6	*14.6 ± 1.7*	0.002
Afatinib	0.005 μM	HCC1954-Ag	70.4 ± 8.3	82.1 ± 9.0	*11.7 ± 2.3*	0.019

ISSN: 1476-4598